ODE models for oncolytic virus dynamics.

Replicating oncolytic viruses are able to infect and lyse cancer cells and spread through the tumor, while leaving normal cells largely unharmed. This makes them potentially useful in cancer therapy, and a variety of viruses have shown promising results in clinical trials. Nevertheless, consistent success remains elusive and the correlates of success have been the subject of investigation, both from an experimental and a mathematical point of view. Mathematical modeling of oncolytic virus therapy is often limited by the fact that the predicted dynamics depend strongly on particular mathematical terms in the model, the nature of which remains uncertain. We aim to address this issue in the context of ODE modeling, by formulating a general computational framework that is independent of particular mathematical expressions. By analyzing this framework, we find some new insights into the conditions for successful virus therapy. We find that depending on our assumptions about the virus spread, there can be two distinct types of dynamics. In models of the first type (the "fast spread" models), we predict that the viruses can eliminate the tumor if the viral replication rate is sufficiently high. The second type of models is characterized by a suboptimal spread (the "slow spread" models). For such models, the simulated treatment may fail, even for very high viral replication rates. Our methodology can be used to study the dynamics of many biological systems, and thus has implications beyond the study of virus therapy of cancers.

[1]  Natalia L. Komarova,et al.  Computational Biology of Cancer: Lecture Notes and Mathematical Modeling , 2005 .

[2]  C. O'Shea,et al.  Viruses – seeking and destroying the tumor program , 2005, Oncogene.

[3]  Artem S Novozhilov,et al.  Population models with singular equilibrium. , 2006, Mathematical biosciences.

[4]  J. Bell,et al.  Oncolytic viruses: what's next? , 2007, Current cancer drug targets.

[5]  J. Kaplan,et al.  Adenovirus-based cancer gene therapy. , 2005, Current gene therapy.

[6]  Dominik Wodarz,et al.  Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. , 2003, Human gene therapy.

[7]  J. Bell,et al.  Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.

[8]  Eugene V Koonin,et al.  Mathematical modeling of tumor therapy with oncolytic viruses: Regimes with complete tumor elimination within the framework of deterministic models , 2006, Biology Direct.

[9]  Zeljko Bajzer,et al.  Mathematical modeling of cancer radiovirotherapy. , 2006, Mathematical biosciences.

[10]  M. Nowak,et al.  Virus dynamics: Mathematical principles of immunology and virology , 2001 .

[11]  H. McCallum,et al.  How should pathogen transmission be modelled? , 2001, Trends in ecology & evolution.

[12]  Zeljko Bajzer,et al.  Modeling of cancer virotherapy with recombinant measles viruses. , 2008, Journal of theoretical biology.

[13]  Nicola Bellomo,et al.  A Survey of Models for Tumor-Immune System Dynamics , 1996 .

[14]  S. Hotte,et al.  Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. , 2003, Current opinion in molecular therapeutics.

[15]  S. Russell,et al.  History of oncolytic viruses: genesis to genetic engineering. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  D. Kirn,et al.  From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. , 2007, Current cancer drug targets.

[17]  D. Wodarz,et al.  Viruses as antitumor weapons: defining conditions for tumor remission. , 2001, Cancer research.

[18]  M. Vähä-Koskela,et al.  Oncolytic viruses in cancer therapy , 2007, Cancer Letters.

[19]  Jianjun Paul Tian,et al.  Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. , 2006, Cancer research.

[20]  B. Fang,et al.  Oncolytic virotherapy for cancer treatment: challenges and solutions , 2005, The journal of gene medicine.

[21]  F. McCormick,et al.  Cancer Specific Viruses and the Development of ONYX-015 , 2003, Cancer biology & therapy.

[22]  J. Bell,et al.  Getting oncolytic virus therapies off the ground. , 2003, Cancer cell.

[23]  Robert A. Gatenby,et al.  Mathematical Modeling in Cancer , 2010 .

[24]  Dominik Wodarz,et al.  Towards Predictive Computational Models of Oncolytic Virus Therapy: Basis for Experimental Validation and Model Selection , 2009, PloS one.

[25]  M. Roberts,et al.  Naturally oncolytic viruses. , 2006, Current opinion in molecular therapeutics.

[26]  Karl Sigmund,et al.  Kolmogorov and population dynamics , 2007 .

[27]  Hyunsuk Shim,et al.  Cancer scene investigation: how a cold virus became a tumor killer. , 2005, Future oncology.

[28]  Lawrence M Wein,et al.  Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. , 2003, Cancer research.

[29]  D. Kirn,et al.  Replicating viruses as selective cancer therapeutics. , 1996, Molecular medicine today.

[30]  Frank McCormick,et al.  Future prospects for oncolytic therapy , 2005, Oncogene.

[31]  R. Martuza,et al.  Oncolytic viral therapies – the clinical experience , 2005, Oncogene.

[32]  Annick Lesne,et al.  Kolmogorov's heritage in mathematics , 2007 .

[33]  A. J. Hall Infectious diseases of humans: R. M. Anderson & R. M. May. Oxford etc.: Oxford University Press, 1991. viii + 757 pp. Price £50. ISBN 0-19-854599-1 , 1992 .

[34]  W. Rom,et al.  Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. , 2001, Human gene therapy.